title: Prothrombin fragment F1 + 2 concentrations for monitoring anticoagulation therapy with heparin.
abstract: We have compared the activated partial thromboplastin time with measurement of prothrombin fragment F1 + 2 concentrations (ELISA assay) during a 24-h period in a group of patients (n = 10) who had undergone elective coronary angioplasty and were anticoagulated post-procedure with heparin 1000 U/h. Four hours after the procedure all the patients were adequately anticoagulated according to activated partial thromboplastin time (median ratio 4.7:1) and the prothrombin fragment F1 + 2 concentration was significantly lower than pre-angioplasty values (0.5 vs 1.4 nmol/l, p = 0.04). At 24 h the median activated partial thromboplastin time ratio was still higher than the pre-procedure value (1.35 vs 0.9, p < 0.01), but the prothrombin fragment F1 + 2 concentration had risen to 2.1 nmol/l, with more variability in individual results within the patient group for the prothrombin fragment F1 + 2 concentration than for activated partial thromboplastin time (interquartile ranges (Q1, Q3) prothrombin fragment F1 + 2, 1.2-2.5; activated partial thromboplastin time, 1.2-1.5). The activated partial thromboplastin time is the standard method of monitoring the anticoagulant effect of heparin but may not fully reflect the functional coagulation status and accurately identify individual patients with less than adequate anticoagulation. Prothrombin fragment F1 + 2 concentrations may provide a more reliable indicator in individual patients of functional coagulation status in certain important situations where anticoagulation is critical such as following complicated coronary angioplasty.
authors.affiliation: Academic Department of Cardiology, Glenfield General Hospital, Leicester, UK.
authors.forename: M J
authors.initials: MJ
authors.lastname: Brack
authors.forename: R S
authors.initials: RS
authors.lastname: More
authors.forename: P J
authors.initials: PJ
authors.lastname: Hubner
authors.forename: A H
authors.initials: AH
authors.lastname: Gershlick
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000097:blood* / Q000188:drug therapy / Q000628:therapy; D016903:Drug Monitoring / Q000379:methods / Q000592:standards*; D004797:Enzyme-Linked Immunosorbent Assay / Q000592:standards*; D005069:Evaluation Studies as Topic; D006493:Heparin / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D010314:Partial Thromboplastin Time; D010446:Peptide Fragments / Q000032:analysis* / Q000096:biosynthesis; D011182:Postoperative Care; D011516:Prothrombin / Q000032:analysis* / Q000096:biosynthesis; D012680:Sensitivity and Specificity; D013997:Time Factors
chemical_list: D010446:Peptide Fragments; C045879:prothrombin fragment 1.2; D011516:Prothrombin; D006493:Heparin